» Articles » PMID: 16397142

GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released from the Myocardium in Association with SMAD Protein Activation

Overview
Journal Circ Res
Date 2006 Jan 7
PMID 16397142
Citations 213
Authors
Affiliations
Soon will be listed here.
Abstract

Here we identified growth-differentiation factor 15 (GDF15) (also known as MIC-1), a secreted member of the transforming growth factor (TGF)-beta superfamily, as a novel antihypertrophic regulatory factor in the heart. GDF15 is not expressed in the normal adult heart but is induced in response to conditions that promote hypertrophy and dilated cardiomyopathy. To elucidate the function of GDF15 in the heart, we generated transgenic mice with cardiac-specific overexpression. GDF15 transgenic mice were normal but were partially resistant to pressure overload-induced hypertrophy. Expression of GDF15 in neonatal cardiomyocyte cultures by adenoviral-mediated gene transfer antagonized agonist-induced hypertrophy in vitro. Transient expression of GDF15 outside the heart by intravenous adenoviral delivery, or by direct injection of recombinant GDF15 protein, attenuated ventricular dilation and heart failure in muscle lim protein gene-targeted mice through an endocrine effect. Conversely, examination of Gdf15 gene-targeted mice showed enhanced cardiac hypertrophic growth following pressure overload stimulation. Gdf15 gene-targeted mice also demonstrated a pronounced loss in ventricular performance following only 2 weeks of pressure overload stimulation, whereas wild-type controls maintained function. Mechanistically, GDF15 stimulation promoted activation of SMAD2/3 in cultured neonatal cardiomyocytes. Overexpression of SMAD2 attenuated cardiomyocyte hypertrophy similar to GDF15 treatment, whereas overexpression of the inhibitory SMAD proteins, SMAD6/7, reversed the antihypertrophic effects of GDF15. These results identify GDF15 as a novel autocrine/endocrine factor that antagonizes the hypertrophic response and loss of ventricular performance, possibly through a mechanism involving SMAD proteins.

Citing Articles

Clinical Insights from Proteomics in Heart Failure.

Lotfinaghsh A, Imam A, Pompian A, Stitziel N, Javaheri A Curr Heart Fail Rep. 2025; 22(1):12.

PMID: 40063168 DOI: 10.1007/s11897-025-00698-w.


GDF15-mediated enhancement of the Warburg effect sustains multiple myeloma growth via TGFβ signaling pathway.

Xue W, Li Y, Ma Y, Zhang F Cancer Metab. 2025; 13(1):3.

PMID: 39871310 PMC: 11770933. DOI: 10.1186/s40170-025-00373-7.


The landscape of plasma proteomic links to human organ imaging.

Fan Z, Chirinos J, Yang X, Shu J, Li Y, OBrien J medRxiv. 2025; .

PMID: 39867388 PMC: 11759249. DOI: 10.1101/2025.01.14.25320532.


Pretreatment with growth differentiation factor 15 augments cardioprotection by mesenchymal stem cells in myocardial infarction by improving their survival.

Huang X, Liang X, Han Q, Shen Y, Chen J, Li Z Stem Cell Res Ther. 2024; 15(1):412.

PMID: 39523354 PMC: 11550561. DOI: 10.1186/s13287-024-04030-6.


Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation.

van Vugt M, Finan C, Chopade S, Providencia R, Bezzina C, Asselbergs F Genome Med. 2024; 16(1):120.

PMID: 39434187 PMC: 11492627. DOI: 10.1186/s13073-024-01395-4.